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Background: Because of the rarity of hilar cholangiocar-
cinoma, its prognostic risk factors have not been suffi-
ciently analyzed. This retrospective study was under-
taken to evaluate various pathologic risk factors which 
influenced survival after curative hepatic resection or 
transplantation. 
Methods: Between 1981 and 1996, 72 patients (43 
males and 29 females) with hilar cholangiocarcinoma 
underwent hepatic resection (34 patients) or transplan-
tation (38 patients) with curative intent. Medical 
records and pathologic specimens were reviewed to ex-
amine the various prognostic risk factors. Survival was 
calculated by the method of Kaplan-Meier using the log 
rank test ~th adjustment for the type of operation. 
Survival statistics were calculated first for each kind of 
. treatment separately, and then combined for the calcu-
lation of the final significance value. 
Results: Survival rates for 1,3, and 5 years after hepatic 
resection were 74%, 34%, and 9%, respectively, and 
those after transplantation were 60%, 32%, and 25%, 
respectively. Univariate analysis revealed that T-3, posi-
tive lymph nodes, positive surgical margins, and pTNM 
stage III and IV were statistically significant poor prog-
nostic factors. Multivariate analysis revealed that 
pTNM stage 0, I, and II, negative lymph node, and 
negative surgical margins were statistically significant 
good prognostic factors. 
For the patients in p TNM stage 0-11 with negative 
surgical margins. 1-, 3-, and 5-year survivals were 80%. 
73%, and 73%. respectively. For patients in pTNM 
stage IV-A with negative lymph nodes and surgical mar-
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gins, 1-,3-, and 5-year survivals were 66%, 37%, and 
37%, respectively. 
Conclusions: Satisfactory longterm survivals can be ob-
tained by curative surgery for hilar cholangiocarcinoma 
either with hepatic resection or liver transplantation. 
Redefining p TNM stage III and IV-A is proposed to 
better define prognosis. (J Am Coll Surg 1998;187: 
358-364. © 1998 by the American College of Sur-
geons) 
Hilar cholangiocarcinoma (Altemeier-Klatskin tu-
morl •2) is an uncommon malignant neoplasm, aris-
ing from the bile duct epithelium of the common 
hepatic duct or its first and second bifurcation. Be-
cause of the rarity of this malignancy, its prognostic 
risk factors have not been completely analyzed. In 
panicular, the reliability of p TNM staging has not 
been evaluable in previous reports.3- 13 We describe 
our IS-year experience with hilar cholangiocarci-
noma, with particular focus on the various risk fac-
tors that influenced the survival of patients after sub-
total hepatic resection, and after total hepatectomy 
with liver replacement. 
METHODS 
Patients 
Between 1981 and 1996, 72 patients with hilar 
cholangiocarcinoma underwent either hepatic resec-
cion (Hx, n = 34) or orthotopic liver transplantation 
(OLT, n=38) with curative intent at the University 
of Pittsburgh Medical Center. There were 43 males 
and 29 females. Ages ranged from 19 to 81 years 
(mean and median, 51 years). Median followup pe-
riod to December 31, 1997 was 76.7±5.0 (SE) 
months. 
Surgical procedures 
Panial hepatectomy (Hx) was the procedure of 
choice for the patients with anatomically resectable 
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tumors who did not have advanced cirrhosis or scle-
rosing cholangitis. Total hepatectomy with liver re-
placement was performed when tumor extension or 
underlying cirrhosis and/or sclerosing cholangitis 
precluded Hx. . 
Hepatic resection. All 34 patients treated with 
subtotal hepatectomy and extrahepatic bile duct ex-
cision also had extensive regional lymph node dissec-
tion in continuity. The biliary system was recon-
structed by anastomosis{es) between the intrahepatic 
duct or ducts (as many as four) and a Roux-en-Y limb 
of jejunum. Only two patients received central resec-
tion, and the remaining 32 patients received lobec-
romy or more extensive resection with techniques 
that have been described elsewhere. 14- 16 The portal 
vein was resected with the tumor and was recon-
structed in five patients, the hepatic artery was recon-
structed in three patients, and both in one patient. 
All 3 portions of the caudate lobe were removed in 22 
patients and 1 or 2 portions were resected in 12 patients. 
Transplantation. These 38 patients could not be 
treated with subtotal hepatectomy. Twenty-seven un-
derwent OLT either because the extent of the tumor 
required total hepatectomy for complete removal 
(n = 14) or because of concomitant advanced cirrho-
sis or severe sclerosing cholangitis, or both, precluded 
partial hepatectomy (n = 13). 
Eleven patients were treated with upper abdom-
inal exenteration and cluster organ transplantation 
(OLT-CL) because of highly unfavorable conditions 
such as lymph node involvement, direct invasion of 
tumor into adjacent organs, or regional metastasis 
(n = 10), or because dense fibrotic reaction caused by 
preoperative radiation therapy made the intraopera-
tive assessment of tumor impossible in a patient with 
sclerosing cholangitis (n = 1). In addition to the liver, 
the composite allografts included various combina-
tions of pancreas, duodenum, and short segments of 
proximal jejunum. The technique of orthotopic liver 
transplantation, including OLT-CL, and the post-
transplant regimens of immunosuppression have 
been described elsewhere. 17-21 
Adjunct therapy 
Forry-four of the 72 patients received adjunct 
external radiation therapy with or without 5-FU sen-
sitization before or after the operation. These regi-
mens were highly variable because of changes in pro-
tocol during the prolonged period of case accrual. 
Pathological characteristics . 
In the 34 patients who underwent hepanc resec-
tion, the pathologic diagnosis of hilar cholangiocar-
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Table I. P TNM Staging of Hilar 
Cholangiocarcinoma * 
Stage T N M 
Stage 0 T-is NO MO 
Stage I Tl NO MO 
Stage II T2 NO MO 
Stage III TI Nl, N2 MO 
T2 NI,N2 MO 
Stage IV A T3 AnyN MO 
Stage IV B AnyT AnyN MI 
'From: Fungn, E1iasziw M, Todo. S. et aI. The Pittsburgh randomized trW 
ofTacrolimus compared to qdosponn for hepatic transplantation. J Am Coil 
Surg 1996:183:117-125, with permission. . . 
M 1 distant metastasis MO, no mewtms; Nl, hepatoduodenalligament: 
N2, other regional: NO, no lymph node involvement; T-is. carcinoma in situ; 
Tl. duct wall: T2. perifibromuscular connective tissue: T3. adjacent structure 
(liver). 
cinoma was established preoperatively in 18 (53%) 
by brush biopsy or previous exploratory operation. 
The suspected diagnosis was confirmed intraopera-
tively in the remaining 16. Similarly, the diagnosis 
was known for certain preoperatively in only 21 of 
the 38 patients (55%) treated with transplantation. 
The definitive diagnosis was established during 
transplantation in 10 (26%) more, but only after 
pathologic examination of the excised liver in. the 
remaining 7 (18%). 
Pathologic findings in the 72 patients were strat-
ified according to p TNM classification and staging22 
(Table 1), and are summarized in Table 2 and 3 as 
determined after all preoperative, operative, and 
pathologic information was complete. Fifty-one of 
the 72 patients (71 %) had pTNM stage IV tumors. 
At the other end of the spectrum, 5 of the 72 patients 
(7%) had p TNM stage 0 or I tumors. Four of the five 
underwent transplantation because of sclerosing 
cholangitis or other disease of the native liver. 
Despite the curative intent of the operations, his-
topathologic examination of the surgical margins re-
vealed malignant cells in 14 of the 34 patients (41 %) 
Table 2. T, N and M Classification of the 72 Patients 
with Hilar Cholangiocarcinoma 
Classification 
T is 
1 
2 
3 
N pos. 
M pos. 
Hx 
(n=34) 
n % 
0 
0 
7 21 
27 79 
14 41 
4 12 
OLT 
(n=27) 
n % 
3 11 
1 4 
9 33 
14 52 
6 22 
I 4 
OLT-CL 
(n=ll) 
n % 
9 
0 
0 
10 91 
5 46 
4 36 
Hx. hepatic resection: is. in situ: OLT. orthotopic liver transpwuation; 
OLT-CL. organ cluster transplantation; pos .. positive. 
-----D---"--"KD--~-----
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Table 3. pTNM Stages of 72 Patients with Hilar 
Cholangiocarcinoma 
Hx OLT OLT-CL 
pTNM (n=34) (n=27) (n=l1) 
Stage % n % n % n 
0 0 11 3 9 
I 0 4 1 0 
II 12 4 33 9 0 
III 9 3 0 0 
IV-A 67 23 48 13 55 6 
IV-B 12 4 4 1 36 4 
Hx, hepatic resection; OLT, orthotopic liver transplantation; OLT-CL, or-
gan cluster transplantation. 
in Hx group, 6 of the 27 OLT recipients (22%), and 
1 of the 11 in OLT-CL group (9%). Five of the 34 
patients in Hx group and 27 of the 38 patients in 
transplant group had concomitant cirrhosis of the 
liver. In addition, one patient in Hx group had liver 
Table 4. Univariate Analysis of Prognostic Risk Factors 
n 
Risk Factor Hx Tx 
Gender 
Male 18 25 
Female 16 13 
Age (y) 
::; 60 19 33 
> 60 15 5 
Associated diseases 
Yes 6 30 
No 28 8 
Tumor 
Tis. 1.2 7 14 
3 27 24 
Lymph node 
Negative 20 27 
Positive 14 11 
Metastasis 
Yes 4 5 
No 30 33 
pTNM stage 
0, I, II 4 14 
III, IV 30 24 
Margins 
Negative 20 31 
Positive 14 7 
Adjuvant therapy 
Yes 26 18 
No 8 20 
Type of operation 
Hx 34 
Tx 38 
fluke, one patient in OLT group had Caroli's disease, 
and two patients in OLT-CL group had choledochal 
cysts that had been resected previously. 
Statistical analysis 
The results were summarized with followup to 
December 31, 1997. Cumulative overall patient sur-
vival rates were calculated by the method of Kaplan-
Meier using the log rank test with adjustment for the 
type of operation (Hx, OLT, and OLT-CL). The ob-
served and expected number of deaths were calcu-
lated first for each type of operation separately, and 
then combined for the calculation of the final log-
rank statistic.23 
Potential risk factors examined by univariate 
analysis are shown in Table 4. The stepwise Cox pro-
portional hazard regression model was used to assess 
the relative prognostic influence on patient survival. 
Values of p<O.05 were considered significant. 
Cumulative survival no. (mo+SE) 
Hx Tx p Value 
21.3 + 4.5 12.7 + 4.9 > 0.61 
31.6 + 6.7 14.3 + 3.1 >0.30 
16.6 + 7.8 4.3 + 4.6 
16.6 + 6.0 14.3 + 3.5 >0.73 
24.2 + 6.7 5.0 + 3.0 
38.8 + 3.8 99.3 + 81.3 < 0.008 
18.0 + 2.4 12.3 + 3.6 
24.3 + 10.4 17.7 + 5.3 < 0.025 
19.1 + 6.3 9.9 + 4.6 
0.8 + 1.2 26.4 + 9.6 > 0.17 
24.3 + 5.3 12.6 + 3.4 
39.4 + 5.9 99.3 + 81.3 < 0.007 
19.1 + 4.6 12.3 + 3.6 
24.2 + 10.3 18.9 + 7.5 < 0.024 
19.1 + 5.0 4.3 + 0.4 
24.3 + 5.1 16.7+5.1 < 0.043 
0.9 + 0.41 12.3 + 3.0 
23.4 + 3.8 > 0.81 
12.7 + 3.4 
Survival analvsis was pe.rtormed with the method of IU.plan-Meier with strantlc:uion bv NpC of operation k~K resecnon or transplantation). Each statistic an:llvsis 
was computed separatelv tor both rvpcs 01 operation, after which the values 01 observed anu expected number of deaths on each strata were com boned with the tin:ll 
log-rank statlSllc. AlI.p val,!-e5 shown were obtained br this procedure. . . 
Hx, hepatic resectIon: I x, transplantalion (orthotopic liver tranSplant3t1on+organ cluster transplantation). 
• 
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-+- HX (n=34) --- OL T (n=27) ..... OLT-CL (n=11) 
100 
p>O.34 
80 
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.. 
> 
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Figure 1. Survivals after hepatic resection (Hx), orthotopic liver 
transplantation (OLT) , and organ cluster transplantation 
(OLT-eLl. 
Because the precise timing of tumor recurrence could 
not be determined in the majority of patients, 
tumor-free survivals could not be calculated. 
RESULTS 
Perioperative mortality 
Five of the 34 patients (14.7%) in Hx group, 6 of 
the 27 patients (22.2%) in OLT group and 2 of the 
11 patients (18.2%) in OLT-CL group died of vari-
ous complications within three months after surgery. 
Overall perioperative mortality was 18%, with no 
statistically significant difference between the three 
types of operation. 
Survival rates 
One- to 5-year cumulative survival rates for the 
34 patients after Hx were 73.5%, 50.0%, 33.9%, 
13.6%, and 9.1%, respectively. Survival at these 
milestones for the 27 patients after OLT were 59.3%, 
40.7%,36.2%,36.2%, and 36.2%, respectively, and 
for the 11 patients after OLT-CL it was 54.6%, 
27.3%,9.1 %,9.1 %, and 9.1 %, respectively (Fig. 1). 
The differences in survival among the three groups of 
patients were not significant (p>0.37). 
The effect of tumor stage 
Survival of the patients with T-is. T-1, or T-2 
tumors tended to be higher than those with T-3 tu-
mors afrer Hx (p<0.096). After transplantation 
(OLT + OLT-CL) , patients in the T-is. T-l, and T-2 
Lategones had signitlcantly better survival 
-+- T3 (n=51) ...... T < 3 (n=21) 
100 
p*<O.008 
80 
~ 60 
1 
'E 40 = ~ 
20 
0 
0 2 3 4 5 
years 
Figure 2. Survival of patients with T3 tumors was significantly 
lower than for those with T-is, I, and 2. 
(p<0.038) than those listed as T-3. When the sur-
vivals of all 72 patients were pooled, survival for the 
51 patients with T-3 tumors was significantly lower 
than for those with T-is, T-l, and T-2 tumors (Fig. 2). 
The unadjusted p value was <0.001 and the adjusted 
p value (p*) according to the types of operation23 was 
<0.008. 
Survival according to the lymph node (N) status 
also is shown separately in Figure 3. Although the 
survival of the patients without lymph node involve-
ment (N-O) was higher than those with positive 
nodes (N-l), the differences did not reach statistical 
significance within either the resection group 
-+- NO (n=47) ...... N1 (n=25) 
100.----------------------------
p*<O.025 
UM+-~~-----------------------
~SM+---~*-~-------------------­
If. 
-.. 
'E 4M+----~l""---~KKKKK----+"""""D"--
= CIl 
OM+---------------~r-----------
l+-----~----~----r_--~~--~ 
o 2 3 4 5 
years 
Figure 3. Survival of patienrs with positive Ivmph nodes (N 1) was 
significantly lower than for those with negative lymph nodes (NO). 
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Figure 4. Survival of patients with stage III and IV were signifi-
cantly lower than for those with less than stage III tumors. 
(p<0.082) or the transplantation group (p<0.16). 
However, when the two groups were pooled (n =72), 
survival with N-O was significantly higher than with 
N-l (Fig. 3) (p<0.023, p*<0.025). 
When the individual factors of tumor depth (T), 
lymph node involvement (N), and metastatic spread 
(M) are combined for pTNM staging,21 survival of 
patients in the resection cohort with pTNM stage III 
and IV tended to be lower than in stages I-II 
(p<0.096). This inverse correlation was statistically 
significant in the transplantation cohort (p<O.038). 
When the 72 cases were pooled, the survival of the 21 
patients with pTNM stages O-II was significantly 
higher than those of 51 patients with stages III and 
IV (Fig. 4) (p<0.002, p*<O.007). 
Positive surgical margins 
After hepatic resection with curative intent, sur-
vival of patients with positive microscopic surgical 
margins was similar to those with negative margins 
(p>0.26). After transplantation with curative intent, 
however, positive surgical margins were associated 
with a significantly reduced survival (p<O.Oll). 
When the resection and transplantation cohorts were 
combined, the adverse effect of a positive margin was 
significant (unadjusted p-value <0.015; adjusted 
p-value [p*]<0.024) (Fig. 5). 
Additional observations 
Although the total of nine patients with regional 
metastasis (local peritoneum or omentum in five, 
intrahepatic metastasis in two, pancreas in one. and 
Roux-en-y jejunum in one) at the time of operation 
(Table 2) was too small for adequate statistical anal-
---Margin (+) (n=21) ~Margin (-) (n=51) 
100---------------------------
p*<O.023 
UM+-~~--------------------
!SM+---~--~~---------------
-: 
R4M+----~:----~~-----
CIl 
OM+-------------~=----------
l+---r--~--_K--~-~ 
o 2 3 4 5 
years 
Figure 5. Survival of patients with negative microscopic margins 
was significantly better than for those with positive margins. 
ysis, it was noteworthy that 4 stage IV-B patients 
survived 353 days, 803 days, 987 days and 2,885 
days after OLT-CL. Another patient is alive with tu-
mor recurrence more than 2 years after hepatic resec-
tion. The remaining four patients died within 3 
months after surgery from various complications. 
Other factors, such as gender, age, concomitant liver 
diseases, and types of operation did not influence 
survival. 
Although overall survival of the patients who re-
ceived adjunct therapy was significantly higher than 
those who did not receive it, the difference became 
insignificant when the patients who died within 3 
months were excluded from the analysis. The results 
of univariate analysis are summarized in Table 5. 
Multivariate analysis revealed the following to be 
good prognostic factors: 1) negative margins, 2) neg-
ative lymph nodes, and 3) T classification ofT-2 or 
less. 
Tumor recurrence 
Forty of the 72 patients died with tumor recur-
rence. In 28, recurrence was confirmed by biopsy or 
necropsy, and in the remaining 12, recurrence was 
clinically determined by various imaging techniques. 
The exact timing of tumor recurrence was often dif-
ficult to determine because of its cryptic nature. 
However, the recurrence was diagnosed histologically 
or clinically within 3 years in 37 of the 40 patients. 
The most common site of tumor recurrence was 
around the hepatic hilum, followed by the liver, lung, 
bone, and skin. Recurrence was first confirmed his-
tologically in one patient 5 years after OLT and in 
another 7 years after Hx. 
r 
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Table 5. Characteristics of 5-year survivors 
Patient Age 
no. (y) Gender Operation pTNM Stage Adjuvant therapy Result 
1 40 Male OLT-CL IV-B (T3, NO, Ml) None Alive, free of tumor, >8 y 
2 43 Male OLT I (Tl, NO, MO) Preop. radiation Alive. free of tumor, >15 y 
3 24 Female OLT II (T2, NO, MO) Preop. radiation Alive. free of tumor, > 11 Y 
4 38 Male OLT II (T2. NO, MO) Postop. radiation Died with tumor, 8 y, 3 rno 
5 51 Male OLT II (T2, NO, MO) Preop. radiation Alive, free of tumor, >7 Y 
6 47 Female OLT II (T2, NO, MO) Preop. radiation Alive, free of tumor, >7 y 
7 35 Male OLT II (T2. NO. MO) Postop. radiation Alive. free of tumor, >7 Y 
8 52 Male OLT II (T2. NO, MO) None Alive, free of tumor, >6 y 
9 44 Female Hx (RTS) N-A (T3, NO, MO) Postop. radiation Died with tumor, 8 y, 9 mo 
10 32 Female Hx (RTS) II (T2, NO, MO) Postop. radiation Alive, free of tumor, >5 y 
. Hx. hepatic resection; OLT. orthotopic liver transplantation; OLT-CL, cluster liver transplantation; Preop .• preoperative; POStOp .• postoperative; RTS, right 
tnscgmentectomy. 
Five-year survivors 
Ten patients have survived more than 5 years 
after surgery. The characteristics of these patients are 
summarized in Table 5. Interestingly, 8 of the 10 
patients were treated with transplantation. 
DISCUSSION 
The poor longterm survival after treatment of hilar 
cholangiocarcinoma has been well documented. The 
5-year survival rate after surgery with curative intent 
ranges in literature reports from 5% to 20%.3-13 This 
has been explained in part by a high perioperative 
mortality due to hepatic failure and sepsis, particu-
larly when a major hepatic resection is combined 
with excision of the extrahepatic bile duct. Preoper-
ative intubation of the obstructed biliary tract, anti-
biotic therapy, and embolization of the portal vein 
branch may reduce the perioperative mortality.24,25 
The principal reasons for the poor results is the 
biologic behavior of the tumor, and its location in a 
strategically critical area. A tumor-free surgical mar-
gin is essential for a reasonable chance of 5-year 
survival.4.6.8.12.26To achieve this, hepatic resection has 
been combined with pancreatoduodenectomy,27 or 
other extended procedures when the tumor has in-
vaded the liver or peripheral region. 12.28.29 
Other more radical options have been liver trans-
plantation plus regionallymphadenectomy4 and or-
gan cluster transplantation. 19.20 In addition to secur-
ing tumor-free margins, liver transplantation or its 
more drastic variations may offer the only hope when 
extensive hilar cholangiocarcinoma is associated with 
advanced cirrhosis of the liver, sclerosing cholangitis, 
or both. Orthotopic liver transplantation with pan-
creatodudenectomy has been performed with less 
mortality and morbidity than the formal organ clus-
ter transplantation.18.29 
The role ofliver transplantation in the treatment 
of hilar cholangiocarcinoma has been controversial 
because of the inefficient use of organs in the face of 
organ shortage.4.8-11.20 Categorical denial of liver 
transplantation for cholangiocarcinoma30 is not jus-
tifiable on medical grounds with the 36% 5-year sur-
vival after 0 LT reported herein (Fig. 1). When and if 
the organ supply is relieved by perfection of xeno-
transplantation, liver or cluster transplantation could 
become the preferred strategy. Meanwhile, the best 
way to improve outcomes and avoid organ allograft 
waste will be by accurate staging, an objective that 
often has been difficult to accomplish. 
Tumor depth (the T in the pTNM) correlated 
well with survival in our study and those by 
others.4.s.7.9-13 Lymph node involvement was an omi-
nous prognostic finding in our patients as has been 
reported by others.4.11 •12 However, the inability to ac-
curately identify lymph node involvement, even in 
the regional nodes, has made this aspect of staging 
unreliable.5-7.9.10 
Multifactorial pTNM staging has correlated in a 
general way with prognosis.4.Il·13 However, it should 
be emphasized how critical is the subanalysis of the 
factors contributing to the pTNM stages III (Tl, T2, 
Nl, N2, MO) and IV-A (T3, Any N, MO). For 
example, in our study of 72 patients, there were 24 
with T3, NO, MO (pTNM stage IV-A). The 1- to 
5-year survival rates of these patients with tumor-free 
lymph nodes were 65%, 35%, 28%, 28%, and 28% 
if the surgical margins were free of tumor. These re-
sults were better than those of patients with positive 
nodes in the ostensibly more favorable p TNM stage 
III and in patients of the same stage IV-B with posi-
tive lymph nodes. 
Leaving the p TNM staging aside. there were 28 
patients with the highly favorable combination of 
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negative surgical margins and negative lymph nodes. 
The 1-, 3-, and 5-year survival of these patients was 
68%, 50%, and 50%, respectively. As with the final 
assessment of the lymph nodes, however, the involve-
ment of the margins often was learned too late to 
influence surgical decisions. Although the operations 
in all 72 cases were performed with curative intent, 
the surgical margins were found by histologic exam-
ination to be positive for malignant cells in 41 % of 
the patients treated with Hx, 22% after OLT, and 9% 
after a LT-CL. 
It is noteworthy that the rate of negative margins 
increased with the extent of surgical extirpation. 
However, because the mortality and morbidity of 
OLT-CL has been excessive/o we have preferred re-
cently to use the less radical procedure of orthotopic 
liver transplantation in combination with pancre-
atoduodenectomy for selected patients with hilar 
cholangiocarcinoma. 
There was no 5-year survival with lymph node 
involvement in our 72 patients (Table 5), although 
there have been several such cases reported in the 
literature.7•11 •12 Extensive nodal dissection combined 
with adjuvant therapy may prove to be beneficial.8 
However, in our series, adjunct radiation therapy did 
not significantly prolong survival when we excluded 
the patients who died within 3 months after surgery. 
CONCLUSIONS 
Negative surgical margins, noninvolvement of 
lymph nodes, and tumor depth ofT-2 or less were 
statistically significant good prognostic factors. A 
5-year survival of 50% can be achieved by hepatic 
resection and orthotopic liver transplantation for hi-
lar cholangiocarcinoma when lymph nodes and sur-
gical margins are free of tumor, in the absence of 
distant metastases. Categorical denial of liver trans-
plantation for hilar cholangiocarcinoma is unjusti-
fied. We suggest redefining p TNM stage III and 
IV-A to better reflect prognosis. 
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